Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients.
alcoholic cirrhosis
cryptogenic cirrhosis
disease-free survival
hepatic resection
hepatocellular carcinoma
hepatoma
meta-analysis
meta-regression
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
overall survival
systematic review
viral hepatitis B
viral hepatitis C
Journal
Annals of surgery open : perspectives of surgical history, education, and clinical approaches
ISSN: 2691-3593
Titre abrégé: Ann Surg Open
Pays: United States
ID NLM: 101769928
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
15
01
2021
accepted:
31
03
2021
medline:
3
5
2021
pubmed:
3
5
2021
entrez:
28
8
2023
Statut:
epublish
Résumé
To systematically review and compare the overall (OS) and disease-free (DFS) survival after hepatic resections for hepatocellular carcinoma (HCC) of patients with nonalcoholic fatty liver disease (NAFLD) versus other risk factors. Different clinical and tumor characteristics are associated with HCC in the setting of NAFLD in comparison to other risk factors. It is still unclear whether these differences impact patient survival after radical hepatectomies. Randomized controlled trials and observational studies published in the English literature between July 1980 and June 2020 were searched using multiple databases. Patients' baseline characteristics and the hazard ratios (HRs) of the OS and DFS were extracted and meta-analyses were performed. Fifteen retrospective cohort studies with a total of 7226 patients were included. Among them, 1412 patients (19.5%) had NAFLD and 5814 (80.4%) had other risk factors (eg, viral hepatitis B or C, alcoholic cirrhosis, or cryptogenic cirrhosis). Summary statistics showed that patients with NAFLD had better DFS (HR = 0.81; 95% CI: 0.70-0.94; After hepatic resections for HCC, NAFLD patients have better DFS and OS than patients with other risk factors. Subgroup analysis and meta-regression suggested that the survival advantage of NAFLD patients was more pronounced in studies published after 2015 and from Asian centers.
Sections du résumé
Objective
UNASSIGNED
To systematically review and compare the overall (OS) and disease-free (DFS) survival after hepatic resections for hepatocellular carcinoma (HCC) of patients with nonalcoholic fatty liver disease (NAFLD) versus other risk factors.
Background
UNASSIGNED
Different clinical and tumor characteristics are associated with HCC in the setting of NAFLD in comparison to other risk factors. It is still unclear whether these differences impact patient survival after radical hepatectomies.
Methods
UNASSIGNED
Randomized controlled trials and observational studies published in the English literature between July 1980 and June 2020 were searched using multiple databases. Patients' baseline characteristics and the hazard ratios (HRs) of the OS and DFS were extracted and meta-analyses were performed.
Results
UNASSIGNED
Fifteen retrospective cohort studies with a total of 7226 patients were included. Among them, 1412 patients (19.5%) had NAFLD and 5814 (80.4%) had other risk factors (eg, viral hepatitis B or C, alcoholic cirrhosis, or cryptogenic cirrhosis). Summary statistics showed that patients with NAFLD had better DFS (HR = 0.81; 95% CI: 0.70-0.94;
Conclusion
UNASSIGNED
After hepatic resections for HCC, NAFLD patients have better DFS and OS than patients with other risk factors. Subgroup analysis and meta-regression suggested that the survival advantage of NAFLD patients was more pronounced in studies published after 2015 and from Asian centers.
Identifiants
pubmed: 37636554
doi: 10.1097/AS9.0000000000000065
pmc: PMC10455059
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e065Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Disclosure: The authors state that they have no proprietary interest in the products named in this article.
Références
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
J Diabetes. 2016 Nov;8(6):824-833
pubmed: 26663605
Dig Liver Dis. 2011 Nov;43(11):875-80
pubmed: 21684821
J Gastroenterol Hepatol. 2020 Nov;35(11):1960-1968
pubmed: 32128882
BMJ. 2018 Jul 18;362:k2817
pubmed: 30021785
Gastroenterology. 2018 Aug;155(2):443-457.e17
pubmed: 29733831
Oncogene. 2006 Jun 26;25(27):3778-86
pubmed: 16799619
J Gastrointest Surg. 2011 Aug;15(8):1450-8
pubmed: 21512848
Heart. 2003 Jun;89(6):681-6
pubmed: 12748237
Cancer Epidemiol. 2020 Aug;67:101775
pubmed: 32623359
Transpl Int. 2017 Jun;30(6):621-637
pubmed: 28295670
Arch Surg. 2005 Apr;140(4):353-8
pubmed: 15837885
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Gastroenterol. 2012 May;47(5):586-95
pubmed: 22328022
Langenbecks Arch Surg. 2015 May;400(4):471-6
pubmed: 25744657
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Transl Gastroenterol Hepatol. 2019 Oct 09;4:72
pubmed: 31728429
J Gastrointest Surg. 2018 Apr;22(4):615-623
pubmed: 29139083
Cell. 2018 Nov 15;175(5):1289-1306.e20
pubmed: 30454647
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
World J Gastroenterol. 2008 Jul 21;14(27):4300-8
pubmed: 18666317
Mayo Clin Proc. 1980 Jul;55(7):434-8
pubmed: 7382552
Br J Surg. 2013 Jan;100(1):113-21
pubmed: 23147992
Aliment Pharmacol Ther. 2017 Nov;46(9):856-863
pubmed: 28857208
Hepatology. 2009 Mar;49(3):851-9
pubmed: 19115377
J Infect Dis. 2020 Jan 14;221(3):389-399
pubmed: 31550363
PLoS One. 2014 Oct 24;9(10):e110257
pubmed: 25343620
Ann Surg Oncol. 2015 Jul;22(7):2253-61
pubmed: 25490872
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Clin Epidemiol. 2013 Sep;66(9):982-93
pubmed: 23683848
Dig Liver Dis. 2015 Oct;47(10):877-83
pubmed: 26250948
J Surg Oncol. 2012 Jul 1;106(1):84-8
pubmed: 22234941
J Am Coll Surg. 2019 Nov;229(5):467-478.e1
pubmed: 31398386
Int J Cancer. 2011 May 15;128(10):2436-43
pubmed: 21128245
J Hepatol. 2014 Jul;61(1):75-81
pubmed: 24607626
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Hepatology. 2015 Dec;62(6):1723-30
pubmed: 26274335
Ann Surg. 2013 May;257(5):929-37
pubmed: 23426336
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069
pubmed: 28960360
Korean J Hepatobiliary Pancreat Surg. 2012 Aug;16(3):98-104
pubmed: 26388916
J Hepatol. 2015 Jul;63(1):93-101
pubmed: 25646890
Ann Surg Oncol. 2015 Jul;22(7):2226-34
pubmed: 25395147
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
BMJ Open. 2012 Jul 31;2(4):
pubmed: 22855629
Hepatol Res. 2017 Apr;47(5):405-418
pubmed: 27288988
Open Forum Infect Dis. 2018 May 23;5(6):ofy120
pubmed: 29992173
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Am J Surg. 2013 Aug;206(2):187-93
pubmed: 23548578
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:119-29
pubmed: 12786623
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Am J Pathol. 2014 Mar;184(3):574-83
pubmed: 24388934
Hepatology. 2010 May;51(5):1593-602
pubmed: 20222092
Transl Gastroenterol Hepatol. 2019 May 17;4:33
pubmed: 31231700
Cleve Clin J Med. 2008 Jun;75(6):431-9
pubmed: 18595551
Hepatology. 2006 Mar;43(3):515-24
pubmed: 16496320
Oncotarget. 2017 Apr 4;8(14):22917-22926
pubmed: 28206970
J Formos Med Assoc. 2019 Apr;118(4):790-796
pubmed: 30482570
Eur J Surg Oncol. 2011 Jul;37(7):618-22
pubmed: 21640545
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Anticancer Res. 2019 Oct;39(10):5639-5643
pubmed: 31570461
Curr Med Res Opin. 2010 Sep;26(9):2183-91
pubmed: 20666689
Cancer. 2016 Nov 15;122(22):3430-3446
pubmed: 27622302
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Hepatol Res. 2010 Jul;40(7):667-85
pubmed: 20633193
Hepatol Res. 2012 Aug;42(8):767-73
pubmed: 22487102
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Arch Pathol Lab Med. 2008 Nov;132(11):1761-6
pubmed: 18976012
Gastroenterology. 2008 Jun;134(7):1908-16
pubmed: 18549877
BMC Cancer. 2015 Apr 01;15:210
pubmed: 25884354
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Ann Hepatol. 2011 Apr-Jun;10(2):119-24
pubmed: 21502672